title: Efficacy and safety of liraglutide 3.0 mg for weight management are similar across races: subgroup analysis across the SCALE and phase II randomized trials.
abstract: The efficacy and safety of liraglutide 3.0 mg versus placebo, as adjunct to diet and exercise, was evaluated in racial subgroups. This post hoc analysis of pooled data from five double-blind randomized, placebo-controlled trials was conducted in 5325 adults with either a body mass index (BMI) ≥27 kg/m(2) plus ≥1 comorbidity or a BMI ≥30 kg/m(2). Statistical interaction tests evaluated possible treatment effect differences between racial subgroups: white (4496, 84.4%), black/African-American (550, 10.3%), Asian (168, 3.2%) and other (111, 2.1%). Effects of liraglutide 3.0 mg on weight loss, associated metabolic effects and safety profile were generally consistent across racial subgroups. All achieved statistically significant mean weight loss at end-of-treatment with liraglutide 3.0 mg versus placebo: white 7.7% versus 2.3%, black/African-American 6.3% versus 1.4%, Asian 6.3% versus 2.5%, other 7.3% versus 0.49%. Treatment effects on weight and cardiovascular risk markers generally showed no dependence on race (interaction test p > 0.05). Adverse events were similar across racial subgroups.
authors.affiliation: Wake Forest School of Medicine, Wake Forest Baptist Medical Center, Winston-Salem, NC, USA.
authors.forename: J
authors.initials: J
authors.lastname: Ard
authors.affiliation: Endocrine Metabolic Associates, Philadelphia, PA, USA.
authors.forename: A
authors.initials: A
authors.lastname: Cannon
authors.affiliation: Division of Preventive Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
authors.forename: C E
authors.initials: CE
authors.lastname: Lewis
authors.affiliation: New York University School of Medicine, New York, NY, USA.
authors.forename: H
authors.initials: H
authors.lastname: Lofton
authors.affiliation: Novo Nordisk A/S, Søborg, Denmark.
authors.forename: T
authors.initials: T
authors.lastname: Vang Skjøth
authors.affiliation: Novo Nordisk Inc, Plainsboro, NJ, USA.
authors.forename: B
authors.initials: B
authors.lastname: Stevenin
authors.affiliation: Columbia University, New York, NY, USA.
authors.forename: X
authors.initials: X
authors.lastname: Pi-Sunyer
mesh_terms: D000328:Adult; D019440:Anti-Obesity Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D044466:Asian People; D044383:Black People; D015992:Body Mass Index; D003131:Combined Modality Therapy / Q000009:adverse effects; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000208:ethnology; D004038:Diet, Reducing / Q000208:ethnology; D004311:Double-Blind Method; D015444:Exercise; D005260:Female; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D006943:Hyperglycemia / Q000208:ethnology / Q000517:prevention & control; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000069450:Liraglutide / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D009765:Obesity / Q000150:complications / Q000188:drug therapy* / Q000208:ethnology / Q000628:therapy; D050177:Overweight / Q000150:complications / Q000188:drug therapy* / Q000208:ethnology / Q000628:therapy; D011236:Prediabetic State / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000208:ethnology; D011788:Quality of Life; D015431:Weight Loss / Q000187:drug effects / Q000208:ethnology; D044465:White People; D001741:Black or African American
chemical_list: D019440:Anti-Obesity Agents; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D000069450:Liraglutide; C517652:hemoglobin A1c protein, human
keywords: antiobesity drug; clinical trial; glucagon-like peptide-1 analogue; liraglutide; obesity therapy; randomized trial